PDCD1 and neoplasm: Although promising efficacy of anti-PD-1 immunotherapy has been reported in locally advanced colon cancer with dMMR tumors (4), the overall response (OR) rates (ORRs) in MSI-H mCRC patients are variable from 28% to 52% (3, 5, 6), which were likely attributed to tumor heterogeneity.